동아ST

Dong-A ST

글로벌 제약기업을 향해 도약하는 동아ST입니다.

Global Business

Our Global Business Division

Leveraging successful product development and robust R&D capabilities,
Dong-A ST is actively expanding into new international markets.

The Global Business Division adopts an R&D-driven approach for global growth, focusing on securing new markets for its proprietary pipeline, which includes DA-3880, growth hormones, and diabetes treatments while maintaining its leadership in the domestic market. Additionally, the division seeks to boost its global presence through enhanced international marketing efforts.

Dong-A ST’s Global Business Division supplies key products such as Bacchus (energy drink) in Cambodia, Growtropin (growth hormone) in Brazil, and DA-3880 (anemia treatment) in Japan. In line with WHO tuberculosis guidelines, the company has expanded its supply of anti-tuberculosis drugs to regions including WHO programs, India, Russia, CIS, and South Africa, having obtained WHO Prequalification (PQ) for Clofazimine, Cycloserine Furthermore, there is a growing demand for Evogliptin, a diabetes treatment, in markets like Russia, Brazil and India

To achieve its vision of becoming a global pharmaceutical leader, Dong-A ST is establishing strategic bases in key global markets, strengthening local sales capabilities, and expanding marketing reach. The company is focused on increasing exports of flagship products and expanding its portfolio across both developed and emerging markets. This includes developing innovative business models, entering advanced markets, adopting diversified recruitment strategies, and fostering global talent through comprehensive training programs, all aimed at solidifying Dong-A ST’s position as a world-class pharmaceutical company.

Global Partnership

North America :: USA

South America :: Brazil, Argentina

Oceania :: Guam, Saipan

Europe :: UK, Germany, Netherlands, Spain, World Health Organization (WHO), Türkiye, Ukraine, Russia/CIS, Georgia

Asia :: Malaysia, Mongolia, Myanmar, Bangladesh, Vietnam, India, Japan, China, Cambodia, Thailand, Pakistan, Philippines, Indonesia, Laos, Sri Lanka

The Middle East and Africa :: Jordan, United Arab Emirates, Namibia, Morocco, Botswana, Syria, Algeria, Iraq, Saudi Arabia, Nigeria, South Africa, Ghana

Importers and Products

No.	Major Importer	Exported Products
1	Cambodia	Bacchus, Olatte
2	Japan	Darbepoetin, Voriconazole, Cyclserine
3	Brazil	Growtropin, Evogliptin
4	Netherlands	Closerin, Clofazimine, Lampremine
5	Russia	Evogliptin, Cycloserine, Terizidone, Bacchus
6	Türkiye	Eporon, Leucostim, Cycloserine
7	China	Closerin, Bacchus, Terizidone
8	India	Evogliptin, Cycloserine, Lampremine
9	Indonesia	Olatte, Eporon
10	Mongolia	Bacchus
11	EU, United States	DMB-3115
12	Philippines	Eporon, Leucostim, Bacchus, Suganon
13	Argentina	Evogliptin
14	Kazakhstan	Cycloserine
15	United States	Bacchus, Demisoda
16	Lebanon	Growtropin, Eporon, Leucostim
17	Ukraine	Growtropin, Stillen, Zydena
18	Iraq	Eporon, Gonadopin
19	Georgia	Leucostim, Growtropin
20	Germany	Terizidone
21	United Kingdom	Cycloserine
22	Mexico	Motilitone
23	Uzbekistan	Gonadopin, Growtropin
24	United Arab Emirates	Growtropin
25	Thailand	Eporon, Suganon
26	Vietnam	Leucostim, Eporon
27	Malaysia	Zydena
28	Saudi Arabia	Growtropin
29	Belarus	Cycloserine
30	South Africa	Stillen
31	France	Closerin
32	Australia	Bacchus
33	Pakistan	Eporon
34	Algeria	Growtropin
35	Yemen	Eporon
36	Morocco	Eporon
37	Jordan	Zydena
38	Syria	Growtropin
39	Nigeria	Gonadopin
40	Canada	Bacchus
Total	32 Countries	16 Products

New drugs

Stillen

Artemisia herb extract
Treatment for gastritis

Zydena

Udenafil
Treatment for erectile dysfunction

Motilitone

Corydaline (marker compound)
Corydails tuber, Pharbitis seed (5:1) 50% Ethanol extract, 30mg
Treatment for functional dyspepsia

Suganon

Evogliptin
Treatment for diabetes
Biologics & Biosimilar

Gonadopin

Recombinant follitropin
Treatment for infertility

Eporon

Recombinant erythropoietin
Treatment for anemia in patients with chronic renal failure
1. Symptomatic anemia
2. Anemia requiring transfusion

Growtropin

Recombinant somatropin
Treatment for growth hormone deficiency

Leucostim

Recombinant filgrastim
1. Treatment of neutropenia in patients undergoing chemotherapy for solid tumors
2. Treatment of neutropenia in patients with hematologic malignancies
(acute myeloid leukemia) who are undergoing chemotherapy
3. Mobilization of hematopoietic stem cells into peripheral blood
4. Post-chemotherapy treatment for mobilization of autologous peripheral blood stem cells
5. Stimulant to increase neutrophil count during hematopoietic stem cell transplantation

DA-3880

Darbepoetin
Treatment for anemia

Imuldosa

Ustekinumab(DMB-3115)
Treatment for psoriasis
Generics

Closerin

Cycloserine
Treatment for tuberculosis

Lampremin

Clofazimine
Treatment for tuberculosis
Drug Substance

Cycloserine

Treatment for tuberculosis

Clofazimine

Treatment for tuberculosis

Terizidone

Treatment for tuberculosis

Evogliptin

Treatment for diabetes

Voriconazole

Treatment for fungal infections

Atorvastatin

Treatment for hyperlipidemia

Energy Drinks/Beverages

Bacchus

Energy drink containing taurine and vitamin b complex

Bacchus Sugar-Free

Sugar-free energy drink containing taurine and vitamin b complex

Bacchus-X

Energy drink containing taurine and ginseng extract

Olatte

Lactose-friendly milky fruit drink with calcium and CCP for enhanced calcium absorption.

Demisoda

Lightly sparkling fruit-rich soda with official vegan certification.

Vitagrand C

Vitamin C drink

Morning Care

Hangover remedy (Gmt-alc 5l 1,600 mg, Milk Thistle)
OTC Products/Nutritional Supplements

Garglin/Children’s
Garglin

Mouthwash

Champ

Cold medicine for children

Benachio

Digestive aid

Acnon Cream
(Acne Ointment)

Topical acne agent

Melatoning Cream

Blemishes and pigmentation cream

PANPYRIN

Antipyretic analgesic

MiNiMAX

Health supplement for children

Medicine Accessibility

Entry in the Medical Market

Dong-A ST is currently exporting novel drugs, generics, and biologics produced in cGMP facilities to approximately 40 countries worldwide through its globally competitive Global Business network.
We have bases in the US, India, and China through which are exploring new market opportunities and expanding our global presence.

We are building a globally competitive pipeline through strategic investments and acquisitions of US pharmaceutical companies, and exploring further opportunities in the US and advanced markets.
India is one of our important bases for global expansion, through which we are exploring opportunities not only in the Indian market but in neighbouring ones.
Our Chinese subsidiary supplies antitubercular medications and supports production of other globally competitive products through partnerships with local CDMOs and clients to ensure a stable supply of drug substances.
Eradication of Global Tuberculosis

As a Stop TB Partner, Dong-A ST is committed to eliminating tuberculosis as a public health problem.
We are the world's largest WHO-qualified supplier of TB medicines, Cycloserine and Clofazimine, and have continuously lowered our prices for wider accessibility to treatment especially in underdeveloped and developing countries.
We are currently establishing a local production model in developing countries through technology transfer to reduce the treatment costs for more
tuberculosis patients.
Supporting Local Health

Dong-A ST engages in various CSR activities for sustainable development
and social value creation.

As a pharmaceutical manufacturer, we unite with local partners and NGOs
to make progress in areas with underdeveloped medical infrastructure.

We donate medicines and daily necessities to hospitals, schools, and
orphanages in Cambodia, navigating the path to better health for local
communities and educational environments for future talents.
In Ethiopia, we are making healthcare accessible to those facing barriers
through provision of our Hicardi ECG monitoring device together with the
Myungsung Christian Medical Center.

Our effort and innovation continue, to expand our CSR activities both
domestically and globally for a better society.
Improving Access to Medicines - Cost Transparency

Dong-A ST is improving access to essential medicines in underdeveloped countries by supplying WHO-certified TB drugs to WHO and high TB burden countries.

By participating in WHO tenders, we are transparently disclosing our supply prices and contributing toward lowering social costs for global tuberculosis eradication. For non-WHO member countries, we set our prices in consideration of their TB treatment strategies and budget.

We are also working with the WHO on a new TB treatment that is currently under review by the WHO, which will lessen the economic burden and enable more patients to access treatment.
Improving Access to Medicines – Supply Chain Improvements

To ensure the quality of medicines supplied overseas, Dong-A ST conducts thorough evaluation to select partners capable of local production and quality/distribution management.
We provide the necessary technical support to our partners to ensure a stable supply of raw materials and pharmaceuticals.

We sincerely consider local production and technology transfers upon request from our partners and developing countries.

At the same time, we have been improving the quality and supply of pharmaceuticals in the neighbouring countries by expanding the supply channel through local production.
Improving Access to Medicines – Post-Market Surveillance

Dong-A ST works closely with all partners to continuously monitor and evaluate adverse drug reactions in developing countries.
We have established a global database that collects data on the safety of marketed medicines.
This allows for analysis of risks and benefits, and aids our partners in meeting regulatory requirements.

Our partners have the capabilities to organize all activities related to pharmacovigilance and post-marketing surveillance.

제품정보
R&D
파이프라인
사업분야
인재채용
IR 자료실
사업관계자
CP
CLEAN :D
PRM
DCMS

DMB-3115 Data Protection Notice

Last Edited on [2023-05-02]

This Privacy Notice describes the personal data that Dong-A ST Co., Ltd. (hereafter “Dong-A”, “us”, “we”, “our”") collects through our website located at http://en.donga-st.com/Main.da that are specific to our product coded DMB-3115 in relation to all clinical trials and regulatory approvals in Europe and how we use and keep safe that information.

Dong-A as the Controller of the personal data has committed to comply with the General Data Protection Regulation N°EU 2016/679 (hereinafter, the "GDPR") and all EU applicable laws and regulations regarding data protection collectively referred as "Data Protection Laws". In compliance with the GDPR, we appointed Data Protection Officer listed below who performs his or her the tasks as required by the GDPR.

With this Privacy Notice, Dong-A aims at ensuring that you understand what personal information is collected about you, how your personal information is used and how it is kept safe.

GENERAL WARNING AND USE OF SOCIAL MEDIA

Access to the Website implies the User’s full and unreserved acceptance of this Privacy Notice (hereinafter the “Notice”), as well as its general terms of use. The User acknowledges having read the information below.

The Notice is valid for all pages hosted on the Website. It is not valid for the pages hosted by third parties to which we may refer and whose privacy notices may differ. Dong-A cannot therefore be held responsible for any data processed on these websites or by third parties. This Notice also applies to any other website that Dong-A may operate.

1. Why, how and for how long do we collect your personal data?

We will only process your personal data in connection with specific purposes. We will keep them for no longer than necessary to fulfill the purposes for which we collected it, including any legal requirements.

Depending on each case, the processing will therefore be as follows:

Purposes	Types of personal data	Legal basis	Retention period
To answer to your queries	Name, email address, Please note that other Personal Data may be processed by Dong-A depending on your request and the information you provide us.	This processing is based on our legitimate interest in answering the requests or queries raised by you through the existing different contact channels We understand that the processing of these data is also beneficial to you to the extent that it enables us to assist you adequately and answer to the queries raised.	We will process your data for the time necessary to meet your request.
For statistical purposes	Aggregate statistical data	We consider that we have lawful interest to understand the way our page is consulted (e.g., how many times our page is consulted, from which country, etc.).	We may export statistical reports, but we guarantee that this is only in an anonymous form.

2. Data sharing

We do not sell or trade your personal data to third parties.

However, Dong-A has contracted with the following Services Providers to manage the Website that may have access to your personal data:

- DA Information for Hosting.

Sharing your personal data as explained above may involve a transfer of personal data to a country outside the European Economic Area (EEA), we are therefore committed to complying with the transfer rules under applicable Data Protection Laws and therefore ensure to:

• Transfer your data to countries where the data recipient is located that has been recognized as adequate by the European Commission; or

• Where a country has not received an adequacy decision from the European Commission, to implement appropriate safeguards, such as the EU Standard Contractual Clauses ("SCCs").

You can contact our DPO (see contact details below) if you want to have more details about the mechanism supporting data transfer.

3. How do we protect your information?

We process your personal data in a confidential manner and provide a sufficient and adequate level of protection of your personal data.

Your personal data is housed behind secured networks and are only accessible by a limited number of persons who have special access rights to such systems and are required to keep the information confidential.

4. Your rights

According to the GDPR, you have the following rights:

- Access. You have the right to obtain confirmation as to whether or not personal data concerning you are being processed, and, where that is the case, information related to the processing of data and a copy of the data being processed.

- Rectification. You have the right to require rectification of inaccurate data about you.

- Right to be forgotten. To obtain the deletion of your personal data in the situations set forth by applicable data protection law.

- Restrict processing. You have the right to restrict processing of data under certain specified circumstances.

- Rectification. You have the right to require rectification of inaccurate data about you.

- Data portability. You have the right to request for the receipt or the transfer to another organization, in a machine-readable form, of your personal data.

- Object to processing. You have the right to object, on grounds relating to your particular situation, at any time to the processing of your data.

- Right to withdraw consent. When you have given your explicit consent for the processing of your data (e.g., Subscription to the Newsletter), you can withdraw it at any time without justification.

Please note that all these rights are not absolute and will be assessed on a case-by-case basis by our Data Protection Officer (DPO).

If you would like to exercise your rights, please let us know by contacting our DPO at dong-a.dpo@mydata-trust.info.

You have also the right to lodge a complaint if you consider that your personal data is not processed in accordance with the GDPR.

If you are an EEA resident: You have the right to lodge a complaint with the Data Protection Authority in the Member State of the European Union of your habitual residence, place of work or place of the alleged infringement.

Please find the contact information of all Authorities in section 6 "Contacts".

5. Changes to this Privacy Notice

This Notice is effective as of the date stated at the top of this page. We may change this Notice from time to time. Please refer back to this Notice on a regular basis.

6. Contacts

If you have any questions or comments about this Notice or our practices regarding your personal data, please contact us.

Dong-A ST Co. Ltd., acting as Controller

64, Cheonho-Daero, Dongdaemun-Gu

Seoul 02587, Republic of Korea

email: st_ciso@donga.co.kr

telephone: +82 2 920 8254

Data Protection Officer

MyData-TRUST SA

Boulevard Initialis, 7 bt 3 – 7000 Mons (BELGIUM)

For EU Data Protection Authorities

https://edpb.europa.eu/about-edpb/about-edpb/members_en